Current Report Filing (8-k)
December 09 2020 - 4:00PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 3, 2020
PRESSURE
BIOSCIENCES, Inc.
(Exact
name of registrant as specified in its charter)
Massachusetts
|
|
001-38185
|
|
04-2652826
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
14
Norfolk Avenue
South
Easton, MA 02375
(Address
of Principal Executive Office) (Zip Code)
(508)
230-1828
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
December 3, 2020, Pressure BioSciences, Inc. (the “Company”) held a special meeting in lieu of the annual meeting
of stockholders (the “Meeting”). At the Meeting, the stockholders voted on the following proposals described in detail
in the Company’s definitive proxy statement for the Meeting filed with the Securities and Exchange Commission on October
30, 2020. As of the record date for the Meeting, there were 3,833,422 shares of the Company’s common stock, par value $0.01
per share, issued and outstanding and entitled to one vote for each share held. The holders of 53.63% of the Company’s shares
of common stock outstanding (2,081,807) submitted votes by proxy or in person at the Meeting, constituting a quorum.
Proposal
1 — Elect one director as a Class III Director until the 2023 Annual Meeting of Stockholders. The election of the director
was approved as follows:
|
|
|
|
|
|
|
|
Shares
voted
|
|
|
|
|
Nominee
|
|
For
|
|
|
Against
|
|
|
Withhold
|
|
|
Broker
Non-Votes
|
|
Richard
T. Schumacher
|
|
|
460,705
|
|
|
|
N/A
|
|
|
|
124,515
|
|
|
|
1,496,587
|
|
Proposal
2: Ratify the appointment of MaloneBailey LLP as the Company’s independent auditors for fiscal year 2020. The ratification
of the appointment of MaloneBailey LLP as the Company’s independent auditor for fiscal year 2020 was approved as follows:
|
|
Shares
voted
|
|
For
|
|
|
2,038,111
|
|
Against
|
|
|
7,449
|
|
Abstain
|
|
|
36,247
|
|
Broker
Non-Votes
|
|
|
N/A
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.
|
PRESSURE
BIOSCIENCES, INC.
|
|
|
|
Dated:
December 9, 2020
|
By:
|
/s/
Richard T. Schumacher
|
|
|
Richard
T. Schumacher
President
and Chief Executive Officer
|
|
|
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024